These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11732401)

  • 1. [Monoclonal antibodies as adjuvant breast cancer therapy. Tumor cells in continuing sleep?].
    MMW Fortschr Med; 2001 Nov; 143(44):56. PubMed ID: 11732401
    [No Abstract]   [Full Text] [Related]  

  • 2. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 3. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 4. [Adjuvant chemotherapy for breast cancer and targeted therapies].
    Dufresne A; Bachelot T; Blay JY
    Rev Prat; 2008 Mar; 58(5):477-8. PubMed ID: 18524101
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
    Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203
    [No Abstract]   [Full Text] [Related]  

  • 7. [Molecular targeting therapy for breast neoplasms].
    Horiguchi J
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():415-21. PubMed ID: 17682186
    [No Abstract]   [Full Text] [Related]  

  • 8. Continuation of trastuzumab beyond disease progression.
    Montemurro F; Faggiuolo R; Redana S; Donadio M; Minischetti M; Durando A; Vietti-Ramus G; Buosi R; Aglietta M
    J Clin Oncol; 2005 Apr; 23(12):2866-8; discussion 2868-9. PubMed ID: 15838006
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
    Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
    Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab faces trials, clinical and otherwise.
    Tuma RS
    J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
    [No Abstract]   [Full Text] [Related]  

  • 12. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
    Seidman AD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138
    [No Abstract]   [Full Text] [Related]  

  • 13. Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.
    Dent R; Clemons M
    Cancer Treat Rev; 2006 Apr; 32(2):144-8. PubMed ID: 16517084
    [No Abstract]   [Full Text] [Related]  

  • 14. Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?
    Mahtani RL; Vogel CL
    J Clin Oncol; 2008 Dec; 26(35):5823-4. PubMed ID: 19001341
    [No Abstract]   [Full Text] [Related]  

  • 15. [Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer].
    Huober J; Jackisch C; Untch M; Möbus V; Wallwiener D; Kaufmann M; Minkwitz G
    Zentralbl Gynakol; 2006 Feb; 128(1):30-7. PubMed ID: 16450285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herceptin in early breast cancer: a call for judicious use.
    Thorat MA
    Natl Med J India; 2005; 18(6):315-7. PubMed ID: 16483033
    [No Abstract]   [Full Text] [Related]  

  • 17. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
    Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
    Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab trials steal show at ASCO meeting.
    Tuma RS
    J Natl Cancer Inst; 2005 Jun; 97(12):870-1. PubMed ID: 15956644
    [No Abstract]   [Full Text] [Related]  

  • 19. [Her2/neu receptor: one of the basic factors rendering tailored therapy feasible in breast cancer patients].
    Kulka J
    Orv Hetil; 2005 Apr; 146(17):785-90. PubMed ID: 17918634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P; Guarneri V; Bengala C
    Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.